MIDDLETOWN, Pa.–(BUSINESS WIRE)–OpZira™, Inc., een toekomstgericht bedrijf gespecialiseerd in oogheelkundige medische hulpmiddelen dat gestoeld is op jarenlang uitmuntend onderzoek, maakte vandaag bekend dat Scott Thielman, PhD, PE, bij het bedrijf i…
Author: Business Wire
Resumen: OpZira, Inc. le da la bienvenida a Scott Thielman, doctor en filosofía, como vicepresidente de desarrollo de productos
MIDDLETOWN, Pensilvania–(BUSINESS WIRE)–OpZira™, Inc., una empresa de dispositivos médicos oftálmicos con visión de futuro cimentada sobre un legado de excelencia en la investigación, anunció hoy que Scott Thielman, doctor en filosofía e ingeniero pr…
OpZira, Inc. heißt Scott Thielman, PhD, als Vice President of Product Development willkommen
MIDDLETOWN, Pennsylvania–(BUSINESS WIRE)–OpZira™, Inc., ein zukunftsorientiertes Unternehmen für ophthalmologische Medizinprodukte, das auf einem Erbe herausragender Forschung aufbaut, gab heute bekannt, dass Scott Thielman, PhD, PE, mit Wirkung zum …
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
INCHEON, Korea–(BUSINESS WIRE)– #Byooviz–Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of B…
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which …
Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development
GHENT, Belgium–(BUSINESS WIRE)–Belgium’s Azalea Vision wins the EIC Accelerator: €7.5M blended finance to take its medical-grade smart contact lens into clinical development.
Hengrui Pharma的创新型环孢素滴眼液恒宜®在中国获批用于治疗干眼症
上海、德国海德堡和马萨诸塞州剑桥–(BUSINESS WIRE)–(美国商业资讯)– 专注于科技创新的全球性制药企业Hengrui Pharma与专注于研发基于其独特EyeSol®无水平台技术的同类首创及同类最佳眼科疗法的生物制药公司Novaliq GmbH (“Novaliq”)今日宣布，2026年6月23日，中国国家药品监督管理局(NMPA)已批准恒宜®（0.1%环孢素滴眼液）用于治疗干眼症患者，旨在增加泪液分泌减少患者的泪液分泌量，并改善疾病体征。 恒宜®是中国首个且目前唯一的无水0.1…
Hengruis Heng Yi® in China als innovative Cyclosporin-Augentropfen zur Behandlung des trockenen Auges zugelassen
SHANGHAI & HEIDELBERG, Deutschland & CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Hengrui Pharma, ein weltweit tätiges Pharmaunternehmen mit Schwerpunkt auf wissenschaftlicher und technologischer Innovation, und die Novaliq GmbH („Novaliq“), ein biopharm…
Samenvatting: Heng Yi® van Hengrui in China goedgekeurd als innovatieve oftalmische cyclosporine-oplossing voor de behandeling van het droge-ogen-syndroom
SHANGHAI & HEIDELBERG, Duitsland & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Hengrui Pharma, een wereldwijd farmaceutisch bedrijf dat zich richt op wetenschappelijke en technologische innovatie, en Novaliq GmbH (“Novaliq”), een biofarmaceutisch bedrijf dat zi…
Resumen: Heng Yi®, de Hengrui, ha sido autorizado en China como una innovadora solución oftálmica a base de ciclosporina para el tratamiento del síndrome del ojo seco
SHANGHÁI, HEIDELBERG (Alemania) y CAMBRIDGE (Massachusetts)–(BUSINESS WIRE)–Hengrui Pharma, una empresa farmacéutica internacional centrada en la innovación científica y tecnológica, y Novaliq GmbH («Novaliq»), una empresa biofarmacéutica especializa…
Riassunto: Heng Yi® di Hengrui è stata approvata in Cina come soluzione oftalmica innovativa di ciclosporina per il trattamento della malattia dell'occhio secco
SHANGHAI e HEIDELBERG, Germania e CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Hengrui Pharma, un’azienda farmaceutica globale che si concentra sull’innovazione scientifica e tecnologica, e Novaliq GmbH (“Novaliq”), un’azienda biofarmaceutica che si conc…
Le produit Heng Yi® de Hengrui obtient l’autorisation de mise sur le marché en Chine en tant que solution ophtalmique innovante à base de cyclosporine pour le traitement de la sécheresse oculaire
SHANGHAI et HEIDELBERG, Allemagne et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Hengrui Pharma, une société pharmaceutique mondiale axée sur l’innovation scientifique et technologique, et Novaliq GmbH (« Novaliq »), une société biopharmaceutique spécia…
ZEISS Meditec Selects Atlas® System from Nirrin Technologies to Modernize Hyaluronic Acid Manufacturing Workflows
BILLERICA, Mass.–(BUSINESS WIRE)–Nirrin Technologies, a developer of analytical tools designed to transform bioprocess analytics, today announced that Hyaltech, a Carl ZEISS Meditec (CZM) company has purchased an Atlas® system to support hyaluronic a…
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development
MIDDLETOWN, Pa.–(BUSINESS WIRE)– #DryAMD–OpZira™ appoints Scott Thielman, PhD, PE, as VP of Product Development to advance technologies for earlier detection and monitoring of ocular disease.
Exonate appoints Olav Hellebø as Chief Executive Officer
CAMBRIDGE, England–(BUSINESS WIRE)–Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the appointment of Olav Hellebø as Chief Executive Offic…
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics Lic…
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
SHANGHAI & HEIDELBERG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #China–Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first…
Tenpoint Therapeutics Launches YUVEZZI™ Direct-to-Consumer Campaign Featuring a Cast of Hand-Crafted Puppets Giving a Voice to the Everyday Fusses of Blurry Close-Up Vision
LONDON & WARREN, N.J.–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the launch of Friends of the …
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the …
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced compl…